Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14064086 | 1.00 | TSHR (0.46) | TSHRTDP1TP53POLBGAA | |
| SCHEMBL18946366 | 1.00 | TSHR (0.46) | TSHRTDP1TP53POLBGAA | |
| SCHEMBL282248 | 0.81 | TSHR (0.48) | TSHRTDP1TP53POLBGAA | |
| SCHEMBL9157801 | 0.80 | LAP3 (0.42) | TSHRTDP1TP53POLBGAA | |
| SCHEMBL1711012 | 0.78 | TSHR (0.50) | TSHRTDP1TP53POLBGAA | |
| SCHEMBL10201143 | 0.78 | TSHR (0.50) | TSHRTDP1TP53POLBGAA | |
| Hydrochloric Acid SCHEMBL9004814 | 0.77 | TSHR (0.43) | TSHRTDP1TP53PPARDALDH1A1 | |
| SCHEMBL492011 | 0.77 | LAP3 (0.48) | TSHRTDP1TP53POLBCYP3A4 | |
| SCHEMBL10385714 | 0.77 | LAP3 (0.50) | TSHRTDP1TP53POLBGAA | |
| SCHEMBL1527604 | 0.76 | TSHR (0.48) | TSHRTDP1TP53POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | YALE UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | YALE UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | YALE UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| WO-2022243379-A1 | THIOL-ENE-BASED POLYMERISABLE COMPOSITION | KARL LEIBINGER MEDIZINTECHNIK GMBH & CO. KG (DE) | 2022-11-24 | — | — | WO | disclosed |
| EP-4091599-A1 | POLYMERIZABLE THIOL-ENE BASED COMPOSITION | Karl Leibinger Medizintechnik Gmbh & Co. Kg (DE) | 2022-11-23 | — | — | EP | disclosed |
| US-20210213532-A1 | THREE-DIMENSIONAL PRINTING | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2021-07-15 | — | — | US | disclosed |
| CN-106459148-B | Novel antimicrobial compounds, reaction media containing the same, and uses thereof | 生物梅里埃公司 | 2020-11-13 | — | — | CN | disclosed |
| US-9969758-B2 | Antimicrobial compounds | BIOMERIEUX (FR) | 2018-05-15 | — | — | US | disclosed |
| US-9969758-B2 | Antimicrobial compounds | BIOMERIEUX (FR) | 2018-05-15 | — | — | US | disclosed |
| US-9969758-B2 | Antimicrobial compounds | BIOMERIEUX (FR) | 2018-05-15 | — | — | US | disclosed |
| CN-1153517-A | Quinoxalindione derivs., their preparation and their use in drugs | SCHERING AG (DE) | 1997-07-02 | — | — | CN | disclosed |
| US-5100881-A | Vinca alkaloids, anticancer, antitumor | ADIR ET COMPAGNIE (FR) | 1992-03-31 | — | — | US | disclosed |
| US-4992243-A | Treating plants with phosphoric acid derivatives | FEDIN MARAT A (SU) | 1991-02-12 | — | — | US | disclosed |
| US-4946833-A | ANTITUMOR AGENTS | ADIR ET CIE (FR) | 1990-08-07 | — | — | US | disclosed |
| EP-0153284-B1 | AMINOALKANEPHOSPHONIC ACIDS AND DERIVATIVES THEREOF AS FUNGICIDAL AGENTS | KenoGard AB (SE) | 1989-08-30 | — | — | EP | disclosed |
| US-4618358-A | CONTROLLING WEEDS IN RICE | CIBA-GEIGY CORPORATION (US) | 1986-10-21 | — | — | US | disclosed |
| US-4530845-A | Substituted with a phenyl group in position 2 | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-07-23 | — | — | US | disclosed |
| US-4501701-A | 20-Isocyano-Δ17(20) -steroids | ROUSSEL UCLAF (FR) | 1985-02-26 | — | — | US | disclosed |
| US-4414226-A | 1,4-Naphtoquinone derivatives and their use in treating coccidiosis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-08 | — | — | US | disclosed |
| EP-0047323-A1 | 1,4-NAPHTHOQUINONE DERIVATIVES AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | MSH2, MGMT, MSH6 | TSHR 3697/4885TDP1 124/4885TP53 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.